Actualización de la guía europea para el diagnóstico y tratamiento | 02 ENE 24

Insuficiencia cardíaca aguda y crónica

El Grupo de Trabajo de la Europeam Society of Cardiology ha hecho una actualización de la guía para el diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica
Autor/a: Marianna Adamo y colaboradores European Heart Journal (2023) 44, 36273639
INDICE:  1. Texto principal | 2. Texto principal
Texto principal

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368

2. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022;387: 1185–95. https://doi.org/10.1056/NEJMoa2203094

3. Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 2023;44:411–21. https://doi.org/10.1093/eurheartj/ehac689

4. Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, et al. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med 2023;388:22–32. https://doi.org/10.1056/NEJMoa2211680

5. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816

6. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286

7. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–27. https://doi.org/10.1056/NEJMoa2204233

8. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038

9. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568–74. https://doi.org/10.1038/s41591-021-01659-1

10. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–29. https://doi.org/10.1056/NEJMoa2025845 12 E S C G u i d e li n e s Downloaded from https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad195/7246292 by guest on 25 August 2023

11. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021;385: 2252–63. https://doi.org/10.1056/NEJMoa2110956

12. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199–209. https://doi.org/10.1016/S0140-6736(22)02083-9

13. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al.   Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019;380:447–58. https://doi.org/10.1056/NEJMoa1810742

14. Jhund PS, Petrie MC, Robertson M, Mark PB, MacDonald MR, Connolly E, et al. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy. JACC Heart Fail 2021;9:518–27. https://doi.org/10.1016/j.jchf.2021.04.005

15. Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 2022;387:1351–60. https://doi.org/10.1056/NEJMoa2206606

16. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022; 400:1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1

17. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA 2023;329:214–23. https://doi.org/10.1001/jama.2022.23924

18. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–42. https://doi.org/10.1056/NEJMoa2300525

19. Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail 2020;22:2383–92. https://doi.org/10.1002/ejhf.2064

20. Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 2021;23:1217–25. https://doi.org/10. 1002/ejhf.2249

21. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail 2022;10:184–97. https://doi.org/10.1016/j.jchf.2021.11.006

22. Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, et al. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med 2022;28:2504–11. https://doi.org/10.1038/s41591-022-02102-9

23. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022;28:1956–64. https://doi.org/10.1038/s41591-022-01971-4

24. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et  al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised  controlled trials. Lancet 2022;400:757–67. https://doi.org/10.1016/S0140- 6736(22)01429-5

25. Masip J, Frank Peacok W, Arrigo M, Rossello X, Platz E, Cullen L, et al. Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care 2022;11:173–85. https://doi.org/10.1093/ehjacc/zuab122

26. Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2022;80:1302–10. https://doi.org/10.1016/j.jacc.2022.07.021

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024